Kumar Manish, Kissoon-Singh Vanessa, Coria Aralia Leon, Moreau France, Chadee Kris
Gastrointestinal Research Group, Department of Microbiology, Immunology, and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Gastrointestinal Research Group, Department of Microbiology, Immunology, and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
Am J Physiol Gastrointest Liver Physiol. 2017 Jan 1;312(1):G34-G45. doi: 10.1152/ajpgi.00298.2016. Epub 2016 Nov 17.
MUC2 mucin is the major glycoprotein in colonic mucus that separates intestinal microbiota from underlying host cells and serves as a food source for some eubacteria. MUC2 deficiency results in impaired epithelial barrier function, imbalance in gut microbiota, and spontaneous colitis. Probiotics have been shown to have a protective effect against colitis. In this study we used Muc2 mucin-deficient (Muc2) and Muc2 littermates to test whether the probiotic mixture VSL#3 requires an intact mucin barrier to exert its beneficial effect. VSL#3 alone reduced basal colonic proinflammatory cytokine levels and improved epithelial barrier function in Muc2 animals. Similarly, in dextran sulfate sodium-induced colitis, VSL#3 dampened the proinflammatory chemokines KC, monocyte chemoattractant protein-1, and macrophage inflammatory protein-2 and upregulated the tissue regeneration growth factors transforming growth factor-β, fibroblast growth factor-1, and vascular endothelial growth factor-A, which accelerated resolution of colitis symptoms in Muc2 animals. Importantly, improved colonic health in VSL#3-treated animals was associated with attenuated reactive oxygen species production by peritoneal macrophages, restoration of antimicrobial peptide gene expression in the small intestine, and increased abundance of bacterial commensals in the gut. The beneficial effects of VSL#3 in Muc2 animals were mediated by acetate, an important short-chain fatty acid produced by gut bacteria. These studies provide evidence for the first time that VSL#3 can enhance epithelial barrier function by dampening the proinflammatory cytokine and chemokine response, accelerating restitution, and altering commensal microbiota in the absence of a functional mucus barrier.
NEW & NOTEWORTHY: It is unclear whether probiotics require an intact mucin barrier to first colonize and/or exert their protective functions. In this study we used mucin-deficient (Muc2) mice to interrogate if the multispecies probiotic mixture VSL#3 could enhance epithelial barrier function. In the absence of a mucus bilayer, VSL#3 dampened proinflammatory and chemokine production, accelerated restitution, and markedly improved gut permeability mediated by the short-chain fatty acid acetate in the colon.
MUC2粘蛋白是结肠黏液中的主要糖蛋白,它将肠道微生物群与下方的宿主细胞分隔开,并作为一些真细菌的食物来源。MUC2缺乏会导致上皮屏障功能受损、肠道微生物群失衡和自发性结肠炎。益生菌已被证明对结肠炎有保护作用。在本研究中,我们使用Muc2粘蛋白缺陷(Muc2)小鼠及其同窝出生的正常小鼠来测试益生菌混合物VSL#3是否需要完整的粘蛋白屏障才能发挥其有益作用。单独使用VSL#3可降低Muc2小鼠结肠基础促炎细胞因子水平并改善上皮屏障功能。同样,在葡聚糖硫酸钠诱导的结肠炎中,VSL#3可抑制促炎趋化因子KC、单核细胞趋化蛋白-1和巨噬细胞炎性蛋白-2,并上调组织再生生长因子转化生长因子-β、成纤维细胞生长因子-1和血管内皮生长因子-A,从而加速Muc2小鼠结肠炎症状的缓解。重要的是,VSL#3治疗的小鼠结肠健康状况改善与腹膜巨噬细胞活性氧产生减少、小肠抗菌肽基因表达恢复以及肠道共生细菌丰度增加有关。VSL#3对Muc2小鼠的有益作用是由乙酸介导的,乙酸是肠道细菌产生的一种重要短链脂肪酸。这些研究首次提供证据表明,在没有功能性黏液屏障的情况下,VSL#3可通过抑制促炎细胞因子和趋化因子反应、加速修复以及改变共生微生物群来增强上皮屏障功能。
尚不清楚益生菌是否需要完整的粘蛋白屏障才能首先定殖和/或发挥其保护功能。在本研究中,我们使用粘蛋白缺陷(Muc2)小鼠来探究多物种益生菌混合物VSL#3是否能增强上皮屏障功能。在没有黏液双层的情况下,VSL#3可抑制促炎和趋化因子产生、加速修复,并通过结肠中的短链脂肪酸乙酸显著改善肠道通透性。